Methods of treating an overweight or obese subject

Abstract

The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis.

What is claimed is: 
     
         1 - 18 . (canceled) 
     
     
         19 . A method of restoring normal metabolic action in an obese patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to said patient. 
     
     
         20 . A method of decreasing body fat in an overweight or obese patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to said patient resulting in body fat reduction, and wherein said patient substantially maintains muscle mass during the body fat reduction. 
     
     
         21 . The method of  claim 20 , wherein the patient retains substantially more muscle mass as compared to body fat reduction in a patient using an energy restricted diet alone. 
     
     
         22 . A method of activating brown fat function and/or increasing brown fat tissue mass in a patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to said patient. 
     
     
         23 - 31 . (canceled) 
     
     
         32 . The method of  claim 19 , wherein said MetAP2 inhibitor is administered subcutaneously or intravenously. 
     
     
         33 . The method of  claim 19  wherein said MetAP2 inhibitor is a substantially irreversible inhibitor. 
     
     
         34 . (canceled) 
     
     
         35 . The method of  claim 19 , wherein said MetAP2 inhibitor is selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable salts thereof. 
     
     
         36 . (canceled) 
     
     
         37 . A method for improving surgical outcome in an obese patient in need thereof by reducing weight of said patient, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to said patient before non-acute surgery, thereby reducing liver and/or abdominal fat in said patient and improving surgical outcome. 
     
     
         38 . The method of  claim 37 , wherein the surgery is chosen from the group: bariatric surgery, cardiovascular surgery, abdominal surgery, or orthopedic surgery. 
     
     
         39 . (canceled) 
     
     
         40 . A method of maintaining a specified weight in a formerly obese patient comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to a patient, wherein the pharmaceutically effective amount is less as compared to an amount needed to reduce weight or body fat. 
     
     
         41 - 43 . (canceled) 
     
     
         44 . The method of  claim 37 , wherein said MetAP2 inhibitor is selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable salts thereof. 
     
     
         45 . The method of  claim 37 , further comprising co-administering an additional weight loss agent. 
     
     
         46 . The method of  claim 37 , further comprising administering a food restricted diet to said patient. 
     
     
         47 . The method of  claim 37 , further comprising: assessing the ketone body production level in said patient; and optionally adjusting the amount administered; thereby optimizing the therapeutic efficacy of said MetAP2 inhibitor. 
     
     
         48 . The method of  claim 37 , wherein said patient incurs greater than or about equal to 20% weight loss after about 6 months of said administration. 
     
     
         49 . (canceled) 
     
     
         50 . The method of  claim 37 , wherein said administration occurs at least weekly. 
     
     
         51 . The method of  claim 37 , wherein said administering comprises administering about 0.005 to about 0.049 mg/kg of a MetAP2 inhibitor selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable salts thereof, to said patient. 
     
     
         52 . (canceled) 
     
     
         53 . (canceled) 
     
     
         54 . The method of  claim 51 , wherein said administering occurs 1, 2, 3 or 4 times a week. 
     
     
         55 . The method of  claim 51 , wherein the 0-(4-dimethylaminoethoxycinnamoyl)fumagillol is administered parenterally or non-parenterally. 
     
     
         56 . (canceled) 
     
     
         57 . (canceled)